osimertinib,tepotinib
astrazeneca,merck
['osimertinib']
 provides w data confirming that double inhibition of egfr and met is needed in case of met mechanism of progression on osimertinib (50 vs 8% orr) #esmo2022 
CEO Gustave Roussy Cancer Campus Aix Marseille University Thoracic oncologist Cofounder Marseille Immunopole Coordinator #ThePioneeRproject Tweets are my own